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Abstract  
The clinical use of liposomal drug delivery vehicles is often hindered by insufficient drug release. 
Here we present the rational design of liposomes optimized for secretory phospholipase A2 (sPLA2) 
triggered drug release, and test their utility in vitro and in vivo. We hypothesized that by adjusting 
the level of cholesterol in anionic, unsaturated liposomes we could tune the enzyme specificity 
based on membrane fluidity, thus obtaining liposomes with an improved therapeutic outcome and 
reduced side effects. Cholesterol is generally important as a component in the membranes of 
liposome drug delivery systems due to its stabilizing effects in vivo. The incorporation of 
cholesterol in sPLA2 sensitive liposomes has not previously been possible due to reduced sPLA2 
activity. However, in the present work we solved this challenge by optimizing membrane fluidity. 
In vitro release studies revealed enzyme specific drug release. Treatment of two different cancer 
cell lines with liposomal oxaliplatin revealed efficient growth inhibition compared to that of 
clinically used stealth liposomes. The in vivo therapeutic effect was evaluated in nude NMRI mice 
using the sPLA2 secreting mammary carcinoma cell line MT-3. Three days after first treatment all 
mice having received the novel sPLA2 sensitive liposome formulation were euthanized due to 
severe systemic toxicity. Thus the present study demonstrates that great caution should be 
implemented when utilizing sPLA2 sensitive liposomes and that the real utility can only be 
disclosed in vivo. The present studies have clinical implications, as sPLA2 sensitive formulations are 
currently undergoing clinical trials (LiPlaCis®).  
 
 
  
Keywords : Secretory phospholipase A2, liposome, triggered release, cancer therapy, drug delivery, 
oxaliplatin 
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1. Introduction 
The clinical use of most conventional chemotherapeutics is often hampered by inadequate 
tumor accumulation and severe toxic effects on healthy organs. Although stable entrapment in long-
circulating liposomes can improve tumor accumulation and tolerability through the enhanced 
permeability and retention (EPR) effect [1,2], drug bioavailability after tumor accumulation remains 
a challenge. Prolonged and uncoordinated release kinetics from the carrier results in drug 
concentrations that are insufficient to achieve significant therapeutic effects [3].  
Currently clinically approved liposomal formulations such as Doxil® have shown moderately 
improved antitumor activity and improved safety [4,5], likely due to disruption of the ammonium-
sulfate gradient and slow diffusion of the drug through the liposomal membrane [6]. However, for 
hydrophilic drugs such as cisplatin and oxaliplatin, which are unable to diffuse over an intact 
liposomal membrane [3], an active trigger mechanism is a requisite for drug release.  
This underlines the paradoxical problem of how to maintain the stability of liposomes in 
circulation and at the same time obtain a high local drug bioavailability in the cancerous tissue. One 
solution is utilizing an endogenous triggered release mechanism that relies on a difference in the 
microenvironment of tumor and healthy tissue, such as the elevated expression of endogenous 
enzymes in cancerous tissues. An attractive candidate is secretory phospholipase A2 type IIA 
(sPLA2-IIA). Both in vivo and in vitro studies have reported elevated levels of sPLA2 in several 
human tumor types, including colon and breast cancer [7–9], as well as elevated levels during tumor 
vascularization [10] and metastases [9].  
sPLA2 catalyzes the hydrolysis of glycerophospholipids at the sn-2 position, yielding 
equimolar amounts of lyso- lipids and free fatty acids [11]. For liposomes this may result in rupture 
of the lipid bilayer and release of the encapsulated drug (Fig. 1). In addition, high local 
concentrations of lyso- lipids and fatty acids may serve as permeability enhancers, thus further 
contributing to transport of the released drug across the cellular membrane [12,13]. However, at too 
high concentrations they can cause cytotoxicity in the form of apoptosis or cellular lysis [14].  
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Fig. 1. Illustration of the secretory phospholipase A2 (sPLA2) concept showing the intended action 
of the sPLA2 activated drug delivery systems. Liposome encapsulated oxaliplatin will circulate until 
it encounters the fenestrated capillaries in the tumor tissue, where it extravasates. Here it encounters 
an elevated level of secretory phospholipase A2 (sPLA2), which hydrolyze the 
phosphoglycerolipids, causing release of the drug. In addition, the hydrolysis products, lyso-lipids 
and free fatty acids, may act as permeability enhancers, thus further contributing to drug transport 
across the cellular membrane.   
 
 
With reference to its substrate specificity, sPLA2 is an interfacially active lipase which 
functions mainly on organized substrates such as lipid bilayers, making it optimal for liposomal 
drug delivery [15]. The enzyme activity is highly dependent on the physical properties and the 
small-scale lateral organization of the lipid membrane [16]. Specifically sPLA2 seems to be 
particularly active at sites of structural defects such as domain boundaries [17,18], and no activity is 
observed in highly rigid cholesterol-doped membranes in the liquid-ordered phase [18,19]. In 
contrast, incorporation of poly(ethylene-glycol) (PEG) in the membrane seems to enhance the 
sPLA2 catalytic activity [16], likely due to an electrostatic interaction between the positively 
charged sPLA2 and the negative charges on the PEG group. In accordance with this, sPLA2 also has 
high specificity towards anionic membranes, particularly at phosphatidylglycerol (PG) levels above 
~ 38 mol% [17]. 
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The concept of sPLA2 sensitive liposomes has been widely studied, especially in vitro 
[13,17,20], and in a few cases in vivo [18,21], for delivery of conventional chemotherapeutics and 
in combination with pro-drug activation [22,23]. Despite this, only one formulation has made it to 
clinical trials. In 2008 LiPlaCis®, a liposomal formulation of cisplatin, entered a clinical phase I 
trial. However, severe renal toxicity and acute infusion reactions following complement activation 
led to a termination of the trials [24]. Despite these adverse effect, LiPlaCis re-entered clinical trials 
in 2013, and are currently recruiting patients (NCT01861496 at clinicaltrials.gov). 
Recently, we have developed a highly sensitive sPLA2 responsive liposome formulation 
loaded with oxaliplatin, which is not limited by nephrotoxicity [25]. However, an in vivo efficacy 
study resulted in severe toxicity, which was suspected to be caused by an excess concentration of 
permeability enhancing components released into the bloodstream, locally in the skin and 
potentially in other tissues (unpublished results).  
In the present study we set out to design liposomes optimized for controlled sPLA2 catalyzed 
drug release, attempting to avoid hemolytic adverse effects, and show the potential of the liposomes 
both in vitro and in vivo. Based on phase diagrams [26,27] of 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC)/cholesterol liposomes, we reasoned that by adjusting the cholesterol level 
we could tune membrane disorder, and thereby closely tune the enzyme sensitivity, thus obtaining 
liposomes with a significant therapeutic effect but without substantial side effects.  
 
2. Materials and Methods 
 
2.1 Materials 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-(1’-rac-glycerol) (sodium salt) (POPG), 1-palmitoyl-2-(dipyrrometheneboron 
difluoride)undecanoyl-sn-glycero-3-phosphocholine (TopFluor PC) and cholesterol were purchased 
from Avanti Polar Lipids, Inc. (Alabama, USA). 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (DSPE-PEG2k) and lyophilized mixture 
of hydrogenated soy phosphocholine (HSPC), cholesterol and DSPE-PEG2k (3:1:1 weight %) were 
acquired from Lipoid GmbH (Ludwigshafen, Germany). Oxaliplatin (OxPt) was purchased from 
Shanghai Yingxuan Chempharm (Shanghai, China). All other chemicals were from Sigma Aldrich 
(Brøndby, Denmark) and of analytical grade. 
 
2.2 Preparation of liposomes 
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Liposomes for in vitro experiments were prepared by thin-film hydration. Briefly, lipids were 
dissolved in chloroform/methanol (9:1), mixed and placed under a gentle stream of nitrogen to 
evaporate the solvent, before being placed under vacuum over night. For drug loading, 15 mg/mL 
OxPt was dissolved in hydration buffer (10 mM HEPES, 5% Glucose, pH 7.4) at 66 °C for 1 h, 
followed by hydration of lipid films at 66 °C for 1 h with vortexing every 15 min. Liposomes were 
downsized by extrusion 21 times through a 100 nm polycarbonate filter at 72 °C. Non-encapsulated 
drug was removed by three days of dialysis (10 mM HEPES, 5% Glucose, 1 mM Calcium 
Gluconate, pH 7.4) using cassettes of 100 kDa molecular cut-off.  
 
For large-scale production for in vivo experiments liposomes were prepared by lyophilization and 
pressure extrusion. Briefly, lipids were dissolved in tert-butanol, mixed, frozen in liquid nitrogen, 
and dried over night. Following hydration, liposomes were downsized by extrusion five times 
through three stacked polycarbonate filters of 200 nm, 100 nm and 100 nm, respectively, using a 
high-pressure extrusion device (Northern Lipids Inc., Burnaby, Canada). Following dialysis, 
liposomes were filtered using 0.45 µm sterile filters. All liposomes were stored at 4 °C. 
 
2.3 Size and zeta potential  
Particle size, polydispersity and zeta potential were analyzed by light scattering using a ZetaPals 
system (Brookhaven Instruments Corporation, NY, USA). Samples were diluted 200-fold (10 mM 
HEPES, 5 % Glucose, pH 7.4), and particle size distribution was determined by five sub runs of 30 
sec each, and zeta potential was determined by 10 sub runs with a target residual of 0.04. 
 
2.4 Drug and lipid concentrations  
The lipid and drug concentrations were determined by measuring the total phosphor and platinum 
content of the samples using inductively coupled plasma mass spectrometry (ICP-MS) using an 
ICAPQ (Thermo ScientificTM, Dreieich, Germany). For phosphor measurements samples were 
diluted 5000-fold in 2% HCl containing 10 ppb gallium as internal standard, and for platinum 
measurements samples were diluted 500,000-fold in 2% HCl containing 0.5 ppb iridium as internal 
standard. Non-encapsulated drug was separated by spin-filtration at 2000 g for 10 min using 
Amicon spin filters with 100,000 kDa molecular cut-off, and diluted 100,000-fold for 
quantification.  
 
2.5 Release of oxaliplatin  
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Oxaliplatin loaded liposomes were diluted in colo205 cell conditioned media or fresh RPMI media, 
both supplemented with 10% FBS, to a final concentration of 500 µM lipid. Samples were mixed 
and incubated at 37 °C for 24 h with gentle magnetic stirring. At time points 0, 6 and 24 h, aliquots 
were removed. Total and released oxaliplatin concentrations were determined by ICP-MS, as 
described above.  
 
2.6 Phospholipid hydrolysis  
Empty liposomes were diluted in buffer (10 mM HEPES, 30 µM CaCl2, 10 µM EDTA, 150 mM 
KCl, pH 7.4), colo205 cell conditioned media or human tear fluid (diluted 30-fold in buffer), to a 
final concentration of 500 µM lipid. Samples were mixed and incubated at 37 °C for 6 h with gentle 
magnetic stirring. Following incubation, 100 µL of the reaction mixture was quickly mixed with 1 
mL chloroform/methanol/acetic acid (2:4:1) to stop the reaction, followed by 1 mL water for 
washing. The organic phase was collected and lipid hydrolysis was analyzed by MALDI-TOF MS. 
Briefly, samples were mixed with matrix (2:3), spotted in triplicates and analyzed by Bruker 
autoflex speed (Bruker Daltonics, Bremen, Germany). As matrix we utilized 2,5-dihydroxybenzoic 
acid (DHB) spiked with sodium trifluoroacetate (NaTFA), dissolved in methanol, with 85 µM 
DPPC as internal reference. Observed MWPOPC: 760.6 (M+H
+), 782.6 (M+Na+). Expected MWPOPC: 
760.6 (M+H+), 782.6 (M+Na+). Observed WPOPG: 793.6 (M+2Na
+), 771.6 (M+H++Na+). 
Expected MWPOPG: 793.5 (M+2Na
+), 771.5 (M+H++Na+).  
 
2.7 Cell culture  
Colo205 and HT-29 human colon carcinoma cell lines were purchased from American Type 
Culture Collection (Virginia, USA), and the MT-3 human mammary carcinoma cell line was a kind 
gift from Dr. Iduna Fichtner. Colo205 and MT-3 cells were maintained in RPMI-1640 and HT-29 
cells in DMEM, both supplemented with 10% heat- inactivated FBS and 1% penicillin/streptomycin 
(pen/strep), in a humidified 5% CO2 atmosphere at 37 °C. Colo205 and HT-29 cells were harvested 
every 3-4 days and used in passages 23-28 and 159-167, respectively. MT-3 cells were harvested 
every 6-7 days and used in passages 31-35. For production of Colo205 cell conditioned media 
(CM), cells were serum-deprived. Briefly, 15-20 million cells were seeded in a T75 flask and 
cultured for 24 h under normal conditions, followed by 24 h in RPMI-1640 supplemented with only 
pen/strep. The conditioned media was collected and stored at -20 °C for further use. Immediately 
before use the CM was supplemented with 10% FBS. 
 
2.8 Cytotoxicity 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
The in vitro anti-proliferative effect was determined using the CellTiter 96 ® AQueous One Solution 
Cell Proliferation Assay (Promega Biotech AB, Stockholm, Sweden), according to the 
manufacturers protocol. Briefly, cells were plated in 96 well plates at a density of 10,000 cells/well 
for HT-29 cells and 15,000 cells/well for MT-3 cells. Following 24 h incubation, media was 
removed and replaced with fresh media or Colo205 CM containing free oxaliplatin, liposomal 
oxaliplatin or empty liposomes. Cells were incubated for 6 h, remaining drug was removed and 
replaced with fresh media, and cells were incubated for a further 66 h before determining the anti-
proliferative effect.  
 
2.9 Cellular uptake 
HT-29 cells were seeded in 12 well plates at 105 cells per well and allowed to adhere for 24 h. 
Empty liposomes labeled with 0.05 mol% TopFluor PC were diluted in pre-warmed DMEM to a 
final concentration of ~ 400 µM lipid (normalized for fluorescence signal), and added to the cells in 
duplicates. At 6 h post treatment, cells were washed twice with PBS, trypsinized, diluted in DMEM, 
pelleted and resuspended in 500 µL PBS. Cellular association was analyzed using a BD AccuriTM 
C6 flow cytometer (BD Biosciences, Erembodegem, Belgium).  Samples were excited using a 488 
nm argon laser and emission was determined using a 533/30 band pass filter. 10,000 events were 
counted per sample. Data were analyzed using the BD Accuri C6 analysis software. 
 
2.10 Light microscopy 
For time-course micrographs, HT-29 cells were seeded in 96 well plates at 10,000 cells per well. 
Following 24 h incubation, media was removed and replaced with CM containing 740 µM empty 
liposomes. Cells were incubated at 37 °C for 72 h. Using an Axiovert 25 inverted light microscope 
(Zeiss, Birkerød, Denmark), pictures were taken 10 min, 1, 2, 4, 6 and 72 h post treatment. Specific 
markings on the microscope were used to obtain pictures of the same area each time.  
 
2.11 Animals 
Five-week-old female NMRI-nu mice were purchased from Taconic (Lille Skensved, Denmark) 
and were allowed to acclimatize in the animal facility for a minimum of one week before initiation 
of experiments. All care and experimentation was performed according to the Danish Animal 
Experimentation Act (equivalent to the U.S. Public Health Service (PHS) Policy on humane Care 
and Use of Laboratory Animals), under the approval of the Danish Animal Welfare Council. 
 
2.12 In vivo efficacy 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
MT-3 cells (107) suspended in 100 µL culture media were injected subcutaneously into the right 
and left flank of anaesthetized mice. When reaching a tumor size of approximately 10 x 10 mm, 
serial transplantations were performed. Donor mice were euthanized and tumors were excised. 
Recipient mice were anaesthetized and tumor sections (~3 x 3 mm) transplanted subcutaneously 
onto the right flank. When tumors reached ~ 200 mm3  (15 days) animals were randomized into 5 
groups of 7 mice and treatment was initiated. Animals received 10 mg/kg oxaliplatin, the liposomal 
equivalent or isotonic glucose solution, by tail vein injection once a week for a total of four 
injections. Tumor size and body weight were monitored 3 times per week. The tumor size was 
measured by an electronic caliper and the tumor volume was determined using the formula: volume 
= (length x width2) / 2, where length is the longest measurement. Animals were euthanized when 
tumors reached 1000 mm3, the body weight decreased by more than 15 % or the animals showed 
signs of discomfort or failure to thrive.  
 
3. Results and Discussion 
 
3.1 Formulation and characterization of liposomes   
According to phase diagrams of POPC/cholesterol liposomes published elsewhere, none or 
minor amounts of cholesterol should render the liposomes in the liquid-disordered phase (Ld), 
whereas high amounts of cholesterol should render the liposomes in the liquid-ordered phase (Lo) 
[26,27]. As sPLA2 has high sensitivity towards anionic membranes with structural defects, we 
hypothesized that by tuning the amount of cholesterol in anionic liposomes, we would tune the 
enzyme sensitivity, thus obtaining a controlled release. To test this, liposomes composed of the 
zwitterionic lipid POPC, the anionic lipid POPG, the polymer DSPE-PEG2000 and 0, 20 or 40 
mol% cholesterol were synthesized. At these cholesterol concentrations, at 37 °C, the liposomes 
should be in the Ld phase, at the boundary of the Ld and Ld-Lo co-existence region and in the Ld-Lo 
co-existence region, respectively [27]. Although, it should be noted that due to large variations in 
proposed phase diagrams in literature, an exact estimate is not possible [26]. Non-hydrolysable 
HSPC/cholesterol/DSPE-PEG2000 (Stealth) liposomes were included as a negative control. All 
liposomes were loaded with the hydrophilic, non-nephrotoxic drug oxaliplatin (OxPt) [25].  
Size distribution, polydispersity index (PDI) and zeta-potential as well as lipid and drug 
concentrations were characterized for each formulation (Table 1). Homogenous size distributions of 
~130 nm and zeta-potentials of ~ -20 mV were obtained for all formulations. The similar zeta-
potential for the neutral and anionic liposomes was unexpected, but is most likely due to a shielding 
effect of the PEG layer. The encapsulation stability was closely followed for all formulations (Table 
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2). The unsaturated liposomes were slightly less stable than the Stealth liposomes, with an 
encapsulation of ~ 95% after three months versus ~ 99% for the Stealth formulation. As the main 
phase transition temperature of the two main lipids (POPC and POPG) is -2 °C, this slight 
instability is likely due to the liposomes being in a fluid phase.  
 
Table 1: Physical/chemical characterization of liposomal formulations of oxaliplatina 
 Abbreviation Size (nm) PDIb Zeta-potential 
(mV) 
O xPt
c
 
(mg/mL) 
Lipid 
(mg/mL) 
ED
d
 
(%) 
Drug-to-lipid 
weight ratio 
        HSPC/Chol/DSPE-PEG2k 
(57:38:5) + OxPt 
Stealth 144 ± 2 0.02 - 19 ± 1 0.72 18.4 98.9 1:26 
POPC/POPG/DSPE-PEG2k 
(55:40:5) + OxPt 
0%chol 133 ± 1 0.03 - 23 ± 1 0.99 14.6 98.6 1:15 
       POPC/POPG/Chol/DSPE-PEG2k 
(35:40:20:5) + OxPt 
20%chol 127 ± 2 0.07 - 19 ± 1 0.92 13.5 99.4 1:15 
        POPC/POPG/Chol/DSPE-PEG2k 
(15:40:40:5) + OxPt 
40%chol 129 ± 1 0.03 - 19 ± 1 0.81 13.8 98.7 1:17 
a
Representative batches of liposomes used for in vitro experiments 
b
Polydispersity index (PDI) 
c
Oxaliplatin (OxPt) 
d
Encapsulated drug (ED) to free drug fraction in percentage 
 
Table 2: Encapsulation stability  
 Months
a 
Encapsulation (%)
b n  
POPC/POPG/DSPE-PEG2k 
(55:40:5) 
0 98  ± 1 2 
1 97.9  ± 0.2 2 
2 96  ± 2 2 
3 94  ± 3 2 
6 96 1 
9 95 1 
    
POPC/POPG/Chol/DSPE-
PEG2k (35:40:20:5) 
0 98.7  ± 0.5 4 
1 97.9  ± 0.9 4 
2 97  ± 1 4 
3 96  ± 2 4 
6 95  ± 3 3 
9 93  ± 3 2 
12 86 1 
    
POPC/POPG/Chol/DSPE-
PEG2k (15:40:40:5) 
0 99 1 
1 97 1 
2 95 1 
3 94 1 
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a
Time after production 
b
Values are mean of n different batches ± standard deviation 
3.2 Enzyme sensitivity and drug release 
The reasoning for utilizing a trigger mechanism is to obtain a controlled, site-specific drug 
release. To investigate if the formulated liposomes posses this quality, the different formulations 
were incubated in the presence or absence of human sPLA2 at 37 °C for 0, 6 and 24 h. Cell 
conditioned growth media (CM) from the human colorectal cancer cell line colo205 was used as the 
enzymatic source [23], and release of oxaliplatin was determined by ICP-MS (Fig. 2A). All three 
formulations exhibited a distinct release in the presence of enzyme, with minor alterations from 6 to 
24 h. The formulations with 0 and 20% cholesterol exhibited a similar release of ~ 80%, whereas 
the formulation with 40% cholesterol showed a release of ~ 50%. It was unexpected that the latter 
showed any release at all as it should be in the Ld-Lo co-existence region and thus be inert to the 
enzyme. However, it is possible that the high negative charge reduces the requisite for disorder. 
Alternatively, the co-existence of Ld and Lo phase does not abolish the enzyme activity, only 
reduces it. Thus the study demonstrates that by applying anionic unsaturated liposomes, 
incorporation of cholesterol is possible without abolishing sPLA2 specificity, and that by changing 
the amount of cholesterol one can alter the liposome release kinetics. This is important since 
incorporation of cholesterol has been reported to increase liposome stability in vivo.   
 In the absence of enzyme, all three formulations gave a release of 20-30%, which increased 
slightly from 6 to 24 h. This release is likely due to leakage upon heating, and seems to represent a 
small burst release during the heating process followed by a slow diffusion when kept at 37 °C. 
This would mean that the formulations would not be entirely stable in circulation. However, as the 
release does not seem to increase much when reaching 37 °C, the liposomal oxaliplatin may still 
represent an improvement compared to the free drug.  
To verify that the enzyme-mediated release was actually due to phospholipid hydrolysis, the 
enzymatic process was analyzed directly by MALDI-TOF MS. Liposomes with 20% cholesterol 
were incubated in the absence or presence of sPLA2 at 37 °C for 6 h. Enzyme from two different 
human sources was used; colo205 CM (~ 75 ± 20 ng/mL [23]) and human tear fluid (54.5 ± 33.9 
µg/mL [28] ). The hydrolysis was estimated based on the relative change in the MALDI-TOF peaks 
after addition of sPLA2 (Fig. 2B and 2C). For both POPC and POPG the peak intensities decreased 
in the presence of enzyme. The decrease was greatest in the presence of tear fluid, which 
    
HSPC/Chol/DSPE-PEG2k 
(57:38:5) 
0 100 1 
1 99 1 
2 99 1 
3 99 1 
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corresponds well with this having the highest enzyme concentration, and for POPG, which 
corresponds well with the enzyme being sensitive towards anionic lipids. The disappearance of the 
di-acyls correlated well with the appearance of the hydrolysis products (data not shown). The 
hydrolysis was not complete for any of the lipids. This could be explained by the liposomes being 
disintegrated before complete hydrolysis, and the enzyme loosing its sensitivity towards the 
disorganized substrate. Control experiments carried out in the absence of enzyme at 0 and 24 h 
incubation proved the absence of non-enzymatic hydrolysis (data not shown).  
In conclusion, the new liposomal formulations do seem to represent an enzyme specific trigger 
mechanism, where release kinetics is partially dependent on the level of cholesterol. It has been 
demonstrated that sPLA2 from porcine pancreas (which is different from human sPLA2-IIA [29,30]) 
is active towards membranes in the Ld-Lo co-existence region, and that hydrolysis results in an 
increase in the Lo phase up to a point where the enzyme looses its sensitivity towards the membrane 
[19]. It is possible that human sPLA2 has a similar activity, and that the liposomes with 40 mol% 
cholesterol eventually shifted from an Ld-Lo co-existence phase to a pure Lo phase, thus resulting in 
reduced release from these. This underlines the possibility of controlling the release kinetics by 
altering the amount of cholesterol.  
 
 
 
Fig. 2. Enzymatic hydrolysis and release of oxaliplatin. A) POPC/POPG/Chol/DSPE-PEG2k 
liposomes with 0, 20 and 40% cholesterol and HSPC/Chol/DSPE-PEG2k (Stealth) liposomes, 
loaded with oxaliplatin, were incubated in the presence or absence of secretory phospholipase A2 (± 
sPLA2) at 37 °C with gentle magnetic stirring for 0, 6 and 24 h. Release of oxaliplatin was 
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determined by ICP-MS. Values are mean of three individual experiments ± SD. 
POPC/POPG/Chol/DSPE-PEG2k (35:40:20:5) liposomes were incubated with colo205 cell 
conditioned media (CM), human tear fluid or no enzyme at 37 °C for 6 h. Hydrolysis of B) POPC 
and C) POPG was determined by MALDI-TOF MS. DPPC was included as internal reference. 
Values are mean of a minimum of three lipid extractions and three spots of each extraction.  
 
3.3 Empty liposomes reveal sPLA2 dependent in vitro cytotoxicity 
The in vitro cytotoxicity of empty sPLA2 sensitive liposomes was investigated, and compared to 
that of non-toxic stealth liposomes. The human colorectal cancer cell line HT-29, which does not 
secrete sPLA2 [31], was used as model cell line. The anti-proliferative effect of increasing 
concentrations of empty liposomes in the absence of sPLA2 was evaluated by MTS staining (Fig. 
3A). All four formulations gave a slight decrease in cell survival, with ~ 80% survival at 740 µM 
lipid. It is not known what this decrease was caused by, but it was also the case for the stealth 
liposomes, and could be due to the presence of liposomes causing minor cellular stress responses. 
Accordingly, it was concluded that the sPLA2 sensitive liposomes (SSLs) per se are non-toxic. 
It has previously been reported that the sPLA2 hydrolysis products may act as permeabilizing 
agents and at high concentrations be cytotoxic, possibly by inducing cellular lysis. It was therefore 
important to investigate the potential cytotoxicity of these. Therefore, the anti-proliferative effect of 
empty liposomes was examined in the presence of enzyme (Fig. 3B). Here the SSLs revealed a 
concentration dependent anti-proliferative effect with only ~ 50% cell survival at 740 µM 
liposomes, as compared to ~ 100% survival for the Stealth liposomes. A distinct difference between 
the three SSL formulations was not observed. At low lipid concentrations (below ~ 200 µM) none 
of the liposomes displayed toxicity. This is likely due to a neutralizing effect of serum albumin, 
which has previously been reported to bind up to five lyso- lipids [32]. Thus at high protein to lipid 
ratios, there may not be an effect of the hydrolysis products. This could be an advantage during 
circulation, as it would avoid disruption of both liposomes and blood-borne cells.  
To investigate if the cytotoxicity at high lipid concentrations was caused by cellular lysis, the 
effect of empty liposomes was followed by time-course microscopy. Cells were treated with 740 
µM empty SSLs for 72 h and imaged 10 min, 1, 2, 4, 6 and 72 h post treatment (Fig. S1). Although 
the cells showed clear signs of toxicity, even after 72 h, there was no apparent lysis (compared to 
complete lysis after two hours for fully saturated lipid formulations, previously studied in our lab). 
This would imply that these sPLA2-sensitive liposomes do not cause lysis in vitro, and that the 
reduced proliferation is either due to increased permeability or induction of apoptosis. We have 
previously observed in vivo toxicity for fully saturated lipid formulations upon sPLA2 activation, 
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and related this to the immense lysis seen in vitro for such formulations. We therefore reasoned that 
the new SSL formulations should be safer in vivo due to their substantially reduced lytic properties.  
 
 
 
Fig. 3. In vitro cytotoxicity of empty sPLA2-sensitive liposomes. HT-29 cells were treated with an 
increasing amount of empty POPC/POPG/Chol/DSPE-PEG2k liposomes with 0 (closed circles), 20 
(open circles) or 40% cholesterol (open diamonds) or Stealth liposomes (closed diamonds), either 
A) in the absence or B) in the presence of colo205 cell conditioned media containig sPLA2. Cell 
survival was evaluated by MTS staining. Values are mean of triplicates with blank (media with 
MTS reagent) subtracted, ± SD. All values are normalized to non-treated cells. The data is 
representative of minimum three separate experiments.  
 
3.4 In vitro cytotoxicity of OxPt-loaded liposomes is enzyme dependent, but not cholesterol 
dependent. 
The in vitro anti-neoplastic effect of oxaliplatin encapsulated in the three SSL formulations was 
examined and compared to that of free oxaliplatin and oxaliplatin encapsulated in stealth liposomes. 
HT-29 cells were treated with increasing concentrations of SSLs with 0% cholesterol (Fig. 4A), 
20% cholesterol (Fig. 4B) or 40% cholesterol (Fig. 4C). Exogenous sPLA2 was added using cell-
conditioned media from colo205 cells. All three SSL formulations revealed a concentration 
dependent, enzyme-specific, anti-proliferative effect that was clearly higher than that of free 
oxaliplatin. This enhanced effect is likely due to the hydrolysis products, which may either be 
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cytotoxic or enhance cell permeability, thus enhancing the drug transport across the cellular 
membrane. It should be noted that even though the SSLs are toxic, there is a clear effect of loading 
them with oxaliplatin. At 25 µM oxaliplatin (corresponding to ~ 185 µM lipid) the loaded SSLs 
resulted in a cell survival of ~ 50% (Fig. 4) as compared to ~ 100% survival for the empty SSLs 
(Fig. 3B). Thus it seems that it is the combination of oxaliplatin encapsulated in SSLs that provide 
the superior anti-neoplastic effect. 
There was no distinct difference between the three SSL formulations, although there might be a 
slight tendency towards a lesser effect of the liposomes with 40% cholesterol (Fig. 4). Thus it 
appears that the amount of cholesterol is not the determining factor in the anti-proliferative effect of 
these SSLs.  
Surprisingly, all three oxaliplatin loaded SSL formulations revealed growth inhibition in the 
absence of enzyme (Fig. 4). Although this inhibition was markedly lower than that of free 
oxaliplatin, it was distinctly higher than that of loaded stealth liposomes. Thus it seems that the 
SSL-induced anti-proliferative effect is not entirely enzyme specific. Flow cytometry revealed a 
small but distinct uptake for all three SSL formulations (Fig. S2). However, the mean fluorescence 
intensity of the stealth liposomes was ~ 3.5-fold higher than that of the SSLs, suggesting that 
unspecific uptake is not a major determinant in sPLA2-independent growth inhibition. As the 
unspecific drug leakage after 6 h at 37 °C was found to be ~ 20% for all three SSL formulations and 
~0 % for the stealth formulation (Fig. 2A), it seems that the unspecific cytotoxicity is primarily due 
to extracellular leakage from unstable liposomes. Although this will effectively reduce the amount 
of liposomal oxaliplatin that can potentially reach the tumor site in vivo, 80% encapsulated drug 
represents a major improvement to free oxaliplatin.  
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Fig. 4. In vitro cytotoxicity of oxaliplatin (OxPt) loaded sPLA2-sensitive liposomes. HT-29 cells 
were treated with an increasing amount of OxPt loaded POPC/POPG/Chol/DSPE-PEG2k liposomes 
with A) 0, B) 20 or C) 40% cholesterol, either in the presence (open circles) or absence (open 
diamonds) of colo205 cell conditioned media containing sPLA2. OxPt in free form (closed circles) 
or encapsulated in HSPC/Chol/DSPE-PEG2k (Stealth) liposomes (closed diamonds) were used as 
controls. Cell survival was evaluated by MTS staining. Values are mean of triplicates with blank 
(media with MTS reagent) subtracted ± SD. All values are normalized to non-treated cells. The data 
is representative of minimum three separate experiments. 
 
3.5 sPLA2 sensitive liposomes are toxic towards mammary carcinoma cell line  
Since there did not seem to be a distinct difference in the anti-proliferative effect of the three 
SSL formulations, only one preparation was selected for further studie s. As the formulation with 
40% cholesterol gave a clearly lower in vitro release, this was excluded. Further, liposomes with no 
cholesterol have been shown to be less stable in circulation, with high protein adsorption and rapid 
clearance [33]. The 20% cholesterol formulation was therefore selected for the final in vitro and in 
vivo studies.  
To investigate the versatility of this formulation, its anti-neoplastic effect was tested on MT-3 
cells, a human, sPLA2 secreting, mammary carcinoma cell line [34]. Cells were treated with 
increasing concentrations of empty SSLs, oxaliplatin loaded SSLs, free oxaliplatin and oxaliplatin 
loaded stealth liposomes (Fig. 5). The empty SSLs showed no toxicity, supporting the 
biocompatibility of these liposomes. Both the loaded SSLs and the free oxaliplatin gave a 
concentration-dependent anti-proliferative effect, with ~ 35% survival at 25 µM oxaliplatin. This is 
a slightly lower survival than what was seen for the HT-29 cells (Fig. 4), indicating that the MT-3 
cells are somewhat more sensitive to treatment by oxaliplatin. At lower drug concentrations (below 
25 µM), the loaded SSLs gave a slightly lower effect than the free drug towards the MT-3 cells.  
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Fig. 5. In vitro cytotoxicity of sPLA2-sensitive liposomes towards sPLA2 secreting MT-3 cells. 
Cells were treated with an increasing amount of free oxaliplatin (OxPt) (closed circles), empty 
(open diamonds) or OxPt loaded (open circles) POPC/POPG/Chol/DSPE-PEG2k (35:40:20:5) 
liposomes or OxPt loaded Stealth liposomes (closed diamonds). Cell survival was evaluated by 
MTS staining. Values are mean of triplicates with blank (media with MTS reagent) subtracted ± 
SD. All values are normalized to non-treated cells.  The data is representative of minimum three 
separate experiments. 
 
3.6 In vivo efficacy 
Though the in vitro data were promising, in vivo evaluation is essential for signifying a clinical 
potential. For this purpose we utilized human MT-3 xenografts transplanted onto nude NMRI mice. 
The MT-3 model was chosen based on its high in vitro sensitivity towards oxaliplatin and in vivo 
sPLA2 expression. Given its clear in vitro anti-neoplastic effect towards MT-3 cells, we evaluated 
the SSL formulation with 20% cholesterol. For comparison we included stealth liposomes. Mice 
received 10 mg/kg oxaliplatin, the liposomal equivalent (Table S1) or isotonic glucose solution, by 
tail vein injection once per week for a total of four injections.  
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Two days after first treatment one mouse having received the SSL formulation succumbed. 
Three days after first treatment the remaining six mice having received the SSL formulation were 
euthanized due to excessive weight loss, dehydration and subcutaneous bleedings (Fig. 6A and B). 
Mice having received control compounds showed no signs of discomfort. The symptoms observed 
for the SSL treated mice were similar to those previously observed for saturated liposomes that 
were highly sensitive to sPLA2. However, for fully saturated liposomes the symptoms did not occur 
until after four administrations of 8 mg/kg every four days. Thus it seems that the new SSL 
formulation is even more toxic than the previous formulations we have investigated, even thought 
the liposomes developed in the present work were less lytic in vitro. 
Macroscopically the mice had excessive amounts of sero-hemorrhagic fluid in the abdominal 
cavity. The livers were enlarged and heterogeneously darker colored and the gall bladder content 
was hemorrhagic in all mice investigated. No abnormalities were observed in the thoracic cavity 
and the urinary bladder content was not hemorrhagic. The liver was formalin fixed and paraffin wax 
embedded and investigated histologically (hematoxylin and eosin staining was performed on 
multiple 5 µm thick sections). Liver sections displayed acute multifocal necrosis of hepatocytes 
with collapse of hepatic sinusoids and peripheral vacuolar degeneration; some hepatocytes also had 
nuclear accumulations reminiscent of inclusion bodies. A distinct inflammatory reaction was 
observed in hepatic sinusoids and around necrotic regions with accumulation of granulocytes (Fig. 
6C). 
Tumor volume measurements were continued for the remaining therapy groups and controls. 
Stealth liposomes displayed improved tumor control compared to untreated controls, although all 
tumors displayed a continuous growth (Fig. S3). In contrast, treatment with free oxaliplatin had no 
effect compared to control. This was somewhat unexpected as the in vitro data suggested high 
sensitivity of MT-3 cells towards oxaliplatin, and support the need and potential of an effective 
drug delivery vehicle in cancer therapy.   
The immense systemic toxicity caused by the new SSL formulation is alarming. Previous 
findings have shown that serum sPLA2 levels are often elevated in cancer patients compared to 
healthy controls [7,35]. Further, it has been shown that many outbred mouse stocks have an intact 
murine sPLA2 gene [36]. Together these findings suggest the possibility of an abnormally high 
sPLA2 serum level, which could induce premature activation of the liposomes in circulation. 
Finally, nude mice are known to accumulate liposomes in the skin [37]. This could give a locally 
very high concentration of lytic agents, resulting in lysis of platelets and subsequent subcutaneous 
bleedings. However, the complete absence of lysis in vitro would still imply that the new SSL 
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formulation should be less prone to induce lysis in vivo, compared to the previously investigated 
saturated lipid formulation, suggesting that there may be another explanation.  
An alternative theory is induction of complement activation. Previous studies have shown that 
liposomes with high negative charge are prone to activate complement [38]. As both the new SSL 
formulation and our previously investigated saturated lipid formulation contain 40 mol% negatively 
charged lipids, they are both within this category. Further, studies have indicated that liposomes 
made up of unsaturated lipids are more prone to activating the complement system compared to 
those prepared by saturated lipids [38]. This could explain why the new SSL formulation induced 
the greatest toxicity. Finally, complement activation has been correlated to platelet activation, 
endothelial damage, microvascular thrombosis and subsequent thrombocytopenia [39], which could 
explain the symptoms in the skin, seen for the SSL treated mice. However, complement activation 
is usually observed as an acute infusion reaction [40], and not as a slowly progressing state.  
Instead of a direct effect of the liposomes, the difference in toxicity could be related to the 
different lysis products. Where hydrolysis of DPPC and DPPG results in the release of palmitic acid 
(PA), hydrolysis of POPC and POPG results in the release of oleic acid (OA). However, a direct 
comparison between the in vitro toxicity of PA and OA demonstrated that OA was significantly less 
damaging to hepatocytes in culture compared to PA [41]. Thus it seems unlikely that the in vivo 
toxicity was a direct cause of OA-induced hepatocyte damage. Instead, intravenous injection of 
oleic acid has been reported to elicit respiratory distress and acute lung injury demonstrated by 
inflammation and macroscopic hemorrhagic lesions on both pulmonary fields  [42–45]. Contrary, no 
association between PA and lung injury seem to be reported. However, no reports seem to exist on 
oleic acid induced liver damage, and in our studies no macroscopic lung damage was observed, 
suggesting a somewhat different mechanism. In relation to this, there is inevitably a difference in 
the pharmacokinetics (PK) and biodistribution (BD) of free oleic acid and that potentially produced 
by hydrolysis of liposomes. Where intravenous administration of free oleic acid leads to 
accumulation in lungs, negatively charged liposomes do not normally demonstrate a high lung 
accumulation. Instead, clearance of liposomes, generally tend to result in a high accumulation in the 
liver and spleen. Although previous experiments in our laboratory have not indicated a relation 
between high liver accumulation of liposomal oxaliplatin and liver damage, other mechanism might 
be important in the case of SSLs. Even though the expression of sPLA2-IIA is likely to be low in 
the liver, the presence of other subtypes might also be able to degrade the liposomes. Especially 
subgroup 1B (sPLA2-IB) has been reported to be expressed in the liver [29]. sPLA2-IB has been 
proposed to have a substrate specificity and activity similar to that of snake venom sPLA2 [30], i.e. 
a high activity and broader specificity compared to human sPLA2-IIA. Thus sPLA2-IB might not 
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only be able to degrade the new SSLs, it might also induce a faster drug release compared to 
sPLA2-IIA. The combination of potentially haemolytic agents and an acute burst release of 
oxaliplatin, causing a locally very high dose of oxaliplatin, could potentially result in acute liver 
failure. Both necrosis and inflammation seen in the liver histopathology implies a liver related 
toxicity. In accordance with this, oxaliplatin-based chemotherapy has been associated with portal 
hypertension, severe hepatic sinusoidal injury, thrombocytopenia and ascites (fluid in the peritoneal 
cavity) in patients [46], i.e. adverse effects similar to those observed here. Furthermore, sPLA2 has 
been reported to leak out of necrotic hepatocytes and induce injury on healthy hepatocytes [47]. 
This could suggest a positive feedback loop, where a few necrotic hepatocytes secrete sPLA2, 
which activates the liposomes, resulting in enhanced hepatocyte death, and subsequent enhanced 
sPLA2 release etc. Combined with the generally higher accumulation of liposomal oxaliplatin 
compared to free oxaliplatin (which to a larger extent is cleared by the kidneys), this could explain 
the extensive toxicity observed.  
Further evidence of a toxicity caused by the combination of SSLs and oxaliplatin could be 
obtained by investigating the effect of administering empty SSLs. However, the severe adverse 
effects imply that such an experiment would be highly unethical.   
Finally, it should be noted that due to the severe toxicity the in vivo study has not been repeated. 
With this in mind, the present study demonstrates that great caution should be imple mented when 
utilizing sPLA2 sensitive liposomes. Even though many have shown potential in vitro, the real 
utility can only be disclosed in vivo. To the best of our knowledge no one has so far provided  
convincing proof of an sPLA2 sensitive formulation with a significantly improved efficacy and 
reduced adverse effects. As such we remain skeptical to the actual potential of sPLA2 sensitive 
liposomes in drug delivery, and considerable caution should be applied with the current 
formulations undergoing clinical evaluation.   
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Fig. 6. In vivo effect of sPLA2 sensitive liposomes. A) Kaplan-Meier analysis of survival. Nude 
NMRI mice bearing MT-3 xenograft tumors were treated with 10 mg/kg free oxaliplatin (OxPt) 
(dotted line), OxPt loaded POPC/POPG/Chol/DSPE-PEG2k (35:40:20:5) liposomes (dashed line) 
or OxPt loaded Stealth liposomes (dotted dashed line) once per week for a total of four treatments.  
Isotonic glucose solution (solid line) was included as control. B) The skin of mouse treated with 
OxPt loaded POPC/POPG/Chol/DSPE-PEG2k (35:40:20:5) liposomes, revealing subcutaneous 
bleedings. C) Liver section from a mouse treated with OxPt loaded POPC/POPG/Chol/DSPE-
PEG2k (35:40:20:5) liposomes. The liver section displays multifocal necrosis of hepatocytes (white 
arrows) with collapse of hepatic sinusoids and vacuolar degeneration of primarily peripheral 
hepatocytes; some of the peripheral hepatocytes also present nuclear inclusion body- like 
accumulations (white arrowheads). Distinct inflammatory reaction is seen in the hepatic sinusoids 
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and around necrotic regions with accumulation of granulocytes (black arrows) (HE stained FFPE 5 
um). 
 
 
4. Conclusion  
 
In conclusion, the present study demonstrates that by applying anionic unsaturated liposomes one 
can incorporate cholesterol into the liposome membranes, which is important for in vivo stability, 
without loosing sPLA2 specificity. Although none of the liposomal formulations revealed cellular 
lysis in vitro, the tested SSLs induced severe toxicity in vivo, indicating that the related toxicity is 
not necessarily associated with lytic agents. Instead, histopathology studies demonstrated extensive 
necrosis and inflammation of the liver, indicating a direct toxic effect on the liver. We hypothesize 
that this is due to high local concentration of oxaliplatin, perhaps in combination with generation of 
lyosolipid and fatty acid hydrolysis products, as a result of extensive liposome activation by sPLA2. 
As such our results demonstrate the necessity of evaluating SSLs in vivo, and underlines existing 
challenges with sPLA2 sensitive liposomal approaches.   
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